573675-29-3

Usage

Uses

Used in Pharmaceutical Industry:
7-Bromopyrido[3,2-d]pyrimidin-4(3H)-one is utilized as a key intermediate in the synthesis of various pharmaceuticals for the development of new drugs. Its unique structure and functional groups contribute to the design and synthesis of potential therapeutic agents, targeting a range of diseases and medical conditions.
Used in Medicinal Chemistry Research:
In the realm of medicinal chemistry, 7-Bromopyrido[3,2-d]pyrimidin-4(3H)-one serves as a valuable compound for research and development. Its structural features allow for the exploration of novel drug candidates, enabling the advancement of pharmaceutical science and the discovery of innovative treatments.
Used in Organic Synthesis:
7-Bromopyrido[3,2-d]pyrimidin-4(3H)-one is employed as a reagent in organic synthesis, facilitating the creation of a variety of specialty chemicals. Its versatility and reactivity make it a useful component in the synthesis of complex organic molecules, contributing to the development of new materials and compounds with diverse applications.
Used in Industrial Applications:
Beyond its pharmaceutical and research applications, 7-Bromopyrido[3,2-d]pyrimidin-4(3H)-one may also find use in other industrial sectors. Its potential applications include the production of specialty chemicals, where its unique properties can be harnessed to create novel products with specific functions and characteristics.

Upstream product

• 64-18-6 formic acid 
• 573675-27-1 3-amino-5-bromopyridine-2-carbonitrile 
• 870997-85-6 3-amino-5-bromo-pyridine-2-carboxylic acid 
• 77287-34-4 formamide 
• 573675-25-9 5-bromo-3-nitropyridine-2-carbonitrile 
• 669066-89-1 3-amino-5-bromopyridine-2-carboxylic acid amide 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 573675-31-7 7-bromo-4-chloro-pyrido[3,2-d]pyrimidine 

Relevant academic research and scientific papers

ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT

The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R′ is an -A1-Cy1 group, or R is an -A1-Cy1 group and R′ is an R1 group, R1 particularly being H or (C1-C6)alkyl group;A1 being an —NH— radical or —NH—CH2— radical;Cy1 particularly being a phenyl group,A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.

CAPSAICIN RECEPTOR AGONISTS

Capsaicin receptor agonists are provided. Such compounds are ligands that may be used to modulate VRl activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to capsaicin receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.